Poor
Needs Revision
Patient Risk:
Moderate
Summary
Partially matches labeled indication and topical/oointment aspects, but includes multiple therapeutic framing claims not supported by the provided label text and narrows the labeled minimum age (3 months and older) to 2 years and older.
Category Scores
Accurate Statements
Eucrisa is used to treat mild to moderate atopic dermatitis (eczema).
Section 1 INDICATIONS AND USAGE
Eucrisa is applied directly to the skin affected by eczema.
Section 2 DOSAGE AND ADMINISTRATION (apply to affected areas; topical use only)
Eucrisa contains crisaborole.
Section 3 DOSAGE FORMS AND STRENGTHS (Ointment: 20 mg of crisaborole per gram...)
Eucrisa is formulated as a topical ointment.
Section 3 DOSAGE FORMS AND STRENGTHS (Ointment...) and Section 2 DOSAGE AND ADMINISTRATION (topical use only)
Unsupported Statements
Crisaborole is a topical treatment intended to reduce inflammation associated with eczema.
Not supported by the provided label sections (only indication and basic administration/formulation text were supplied).
Eucrisa is positioned as a non-steroid topical option for atopic dermatitis.
Not supported by the provided label sections.
Contradictions
Low
AI Statement
Eucrisa is used in people aged 2 years and older.
Label Reference
Section 1 INDICATIONS AND USAGE (adult and pediatric patients 3 months of age and older).
Important Omissions
Dosage instructions (e.g., apply a thin layer twice daily) and the labeled post-response consideration (reduce to once daily after achieving clinical effect).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Therapeutic framing is unsupported by the provided label excerpts, and the age statement narrows the labeled eligible population (3 months and older to 2 years and older), which could affect appropriate use. Medication delivery/dosing details and topical route restriction (ophthalmic/oral/intravaginal) were not fully addressed in the claims provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Needs Revision
Primary Issue
Age range and unsupported therapeutic positioning claims not present in the provided label text.
Suggested Improvement
Replace the age claim with the labeled “adult and pediatric patients 3 months of age and older,” remove or rephrase unsupported statements (inflammation intent; non-steroid positioning), and include label-supported dosing language (thin layer twice daily; consider once daily after clinical effect) and topical-only route restriction if relevant.